HSP90AB1 and cancer: Dual inhibition of HSP90 and kinases could therefore be a very attractive strategy for cancer and potentially other diseases, and drug combinations have been suggested (Butler et al., 2015; Courtin et al., 2016; Schwartz et al., 2015; Wang et al., 2016).